These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 10396687)

  • 41. [A 6-year study of glycopeptides-resistant enterococci in 3 intensive care units of the University Hospital of Montpellier].
    Godreuil S; Marchandin H; Boulier A; Boumzebra A; Campos J; Jean-Pierre H
    Pathol Biol (Paris); 2007 Nov; 55(8-9):418-23. PubMed ID: 17905540
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2000)].
    Shimada K; Terai T; Igari J; Inoue H; Nakadate T; Oguri T; Suwabe A; Obata R; Ikemoto H; Ohno I; Okada S; Hayashi K; Mori T; Nakano K; Arakawa M; Gejyo F; Igarashi K; Yokouchi H; Okada M; Ito A; Sumitomo M; Aoki N; Matsushima T; Niki Y; Kitamura N; Suga M; Suzuki Y; Karasawa Y; Tosaka M; Nakata K; Nakatani T; Kohno S; Tomono K; Miyazaki Y; Inagawa H; Hirakata Y; Aoki S; Matsuda J; Kudo K; Kobayashi N; Kinoshita T; Konosaki H; Nasu M; Nagai H; Kobayashi H; Kawai S; Takayasu S; Hiramatsu K; Nakano T
    Jpn J Antibiot; 2002 Oct; 55(5):537-67. PubMed ID: 12532637
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Vancomycin resistant enterococci].
    Fujita N; Komori T; Ike Y; Yoshimura M
    Rinsho Byori; 1998 Jul; 46(7):629-36. PubMed ID: 9721528
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1999)].
    Shimada K; Nakano K; Ohno I; Okada S; Hayashi K; Yokouchi H; Arakawa M; Gejyo F; Igarashi K; Ikemoto H; Mori T; Okada M; Ozaki K; Igari J; Aoki N; Oguri T; Kitamura N; Terai T; Suzuki Y; Inoue H; Nakadate T; Karasawa Y; Ito C; Yoshida T; Nakata K; Nakatani T; Inagawa H; Ando M; Suga M; Sato K; Kudo K; Kobayashi N; Tosaka M; Hasegawa M; Kohno S; Tomono K; Miyazaki Y; Kobayashi H; Kawai S; Takayasu S; Hirakata Y; Matsuda J; Mochida C; Ito A; Sumitomo M; Nasu M; Nagai H; Matsushima T; Niki Y; Hiramatsu K; Nakano T
    Jpn J Antibiot; 2001 Jul; 54(7):331-64. PubMed ID: 11560054
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antimicrobial susceptibilities of clinical isolates of vancomycin-resistant enterococci in Taiwan.
    Hsueh PR; Wu JJ; Lu JJ; Teng LJ; Luh KT
    J Formos Med Assoc; 1999 Jan; 98(1):45-8. PubMed ID: 10063273
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria].
    Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2003 Oct; 56(5):437-57. PubMed ID: 14692380
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combining quinupristin/dalfopristin with other agents for resistant infections.
    Brown J; Freeman BB
    Ann Pharmacother; 2004 Apr; 38(4):677-85. PubMed ID: 14990776
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro activity of daptomycin against Staphylococcus aureus and vancomycin-resistant Enterococcus faecium isolates associated with skin and soft tissue infections: first results from India.
    Dhawan B; Gadepalli R; Kapil A
    Diagn Microbiol Infect Dis; 2009 Oct; 65(2):196-8. PubMed ID: 19748433
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intra-hospital dissemination of quinupristin/dalfopristin- and vancomycin-resistant Enterococcus faecium in a paediatric ward of a German hospital.
    Werner G; Klare I; Spencker FB; Witte W
    J Antimicrob Chemother; 2003 Jul; 52(1):113-5. PubMed ID: 12805253
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Investigation into the efficacy of disinfectants against MRSA and vancomycin-resistant enterococci.
    Goroncy-Bermes P
    Zentralbl Hyg Umweltmed; 1998 Dec; 201(4-5):297-309. PubMed ID: 9916285
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.
    Garrison MW; Nuemiller JJ
    Int J Antimicrob Agents; 2007 Feb; 29(2):191-6. PubMed ID: 17174074
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
    Dowzicky MJ; Park CH
    Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Persistence of vancomycin-resistant Enterococcus faecium gastrointestinal tract colonization in antibiotic-treated mice.
    Dever LL; Handwerger S
    Microb Drug Resist; 1996; 2(4):415-21. PubMed ID: 9158812
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro susceptibilities of clinical isolates of vancomycin-resistant enterococci.
    Evans PA; Norden CW; Rhoads S; Deobaldia J; Silber JL
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1406. PubMed ID: 9174211
    [No Abstract]   [Full Text] [Related]  

  • 56. Effect of the Minimum Inhibitory Concentration of Vancomycin on the Clinical Outcome of
    Hoshi T; Watanabe K; Fukumura Y; Miyazaki K; Takahashi M; Taniguchi S; Wada N; Miura M; Kato S; Yamada K; Fujii S; Sato H
    In Vivo; 2023; 37(5):2197-2202. PubMed ID: 37652497
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Antimicrobial resistance surveillance: VIRA STUDY 2006].
    Picazo JJ; Betriu C; Rodríguez-Avial I; Culebras E; Gómez M; López F;
    Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):617-28. PubMed ID: 17194387
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antimicrobial resistance in gram-positive pathogens isolated in the UK between October 1996 and January 1997.
    Andrews J; Ashby J; Jevons G; Lines N; Wise R
    J Antimicrob Chemother; 1999 May; 43(5):689-98. PubMed ID: 10382891
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Selection of Enterococcus faecium strains with stable and unstable resistance to the streptogramin RP 59500 using stepwise in vitro exposure.
    Millichap J; Ristow TA; Noskin GA; Peterson LR
    Diagn Microbiol Infect Dis; 1996 May; 25(1):15-20. PubMed ID: 8831040
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Susceptibility of enterococci, methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae to the glycylcyclines.
    Weiss WJ; Jacobus NV; Petersen PJ; Testa RT
    J Antimicrob Chemother; 1995 Jul; 36(1):225-30. PubMed ID: 8537270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.